Walvax Biotechnology Co., Ltd. (SHE:300142)

Walvax Biotechnology Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Total Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 15, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Market Capitalization	20,744	17,449	19,320	37,601	64,274	89,423
Market Cap Growth	5.28%	-9.69%	-48.62%	-41.50%	-28.12%	50.25%
Enterprise Value	21,203	17,300	18,563	36,117	62,959	88,584
Last Close Price	12.97	10.77	11.92	23.17	39.60	55.35

Price Ratios

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 15, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
PE Ratio	110.53	98.17	135.90	89.66	88.21	209.06
Forward PE	-	50.16	37.75	42.75	54.68	56.13
PS Ratio	9.89	7.22	6.85	9.14	12.64	25.82
PB Ratio	2.83	1.83	1.68	3.30	5.85	8.94
P/TBV Ratio	3.39	2.25	2.31	4.57	8.15	11.16
P/FCF Ratio	1125.60	-	39.71	199.74	582.65	-
P/OCF Ratio	37.84	35.54	18.64	33.16	53.50	126.79

EV Ratios

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 15, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
EV/Sales Ratio	10.11	7.15	6.58	8.78	12.38	25.58
EV/EBITDA Ratio	38.42	35.63	47.89	32.22	44.27	95.49
EV/EBIT Ratio	112.29	165.82	773.04	43.46	53.63	111.82
EV/FCF Ratio	1150.54	-	38.16	191.86	570.72	-

Financial Efficiency

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 15, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Debt / Equity Ratio	0.18	0.04	0.04	0.07	0.04	0.03
Debt / EBITDA Ratio	2.35	0.78	1.19	0.70	0.32	0.34
Debt / FCF Ratio	70.47	-	1.01	4.28	4.19	-
Net Debt / Equity Ratio	0.02	-0.13	-0.28	-0.31	-0.31	-0.31
Net Debt / EBITDA Ratio	0.20	-2.63	-8.44	-3.17	-2.40	-3.37
Net Debt / FCF Ratio	5.94	68.53	-6.72	-18.90	-30.92	7.85
Asset Turnover	0.17	0.18	0.19	0.27	0.35	0.30
Inventory Turnover	0.83	0.95	0.83	0.74	0.72	0.60
Quick Ratio	1.70	2.01	2.63	2.37	2.24	2.07
Current Ratio	2.07	2.35	2.98	2.73	2.55	2.37
Return on Equity (ROE)	1.97%	1.19%	1.52%	4.57%	8.94%	6.74%
Return on Assets (ROA)	0.96%	0.49%	0.10%	3.36%	5.06%	4.25%
Return on Invested Capital (ROIC)	1.93%	0.95%	0.28%	9.20%	14.24%	10.50%
Return on Capital Employed (ROCE)	2.20%	1.00%	0.20%	6.70%	9.90%	7.60%

Yields

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 15, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Earnings Yield	0.91%	1.02%	0.74%	1.11%	1.13%	0.48%
FCF Yield	0.09%	-0.11%	2.52%	0.50%	0.17%	-0.45%
Dividend Yield	1.18%	1.44%	0.08%	0.04%	0.03%	0.05%
Payout Ratio	545.28%	444.39%	28.80%	4.76%	6.88%	19.48%
Buyback Yield / Dilution	-1.20%	-0.05%	0.06%	0.21%	-1.93%	-0.90%
Total Shareholder Return	-0.01%	1.39%	0.15%	0.26%	-1.91%	-0.85%

Data Source: S&P Global Market Intelligence Last updated: Aug 28, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 16, 2026

Data Sources Report a data error